Sticky Issues: What APs Need to Know About Anticoagulants and Patients With Cancer
Presented by Val R. Adams, PharmD, FCCP, FHOPA, BCOP
From University of Kentucky, Lexington, Kentucky
J Adv Pract Oncol 2021;12(3):262–265 |
© 2021 Harborside™
During the JADPRO Live Virtual 2020 conference, Val R. Adams, PharmD, FCCP, FHOPA, BCOP, discussed how to determine which patients with cancer should be treated with direct oral anticoagulants (DOACs), the similarities and differences between the DOACs, and recent data on the prevention and treatment of cancer-associated venous thromboembolism.
For access to the full length article, please sign in